US 12,134,786 B2
Methods of predicting ancestral virus sequences and uses thereof
Luk H. Vandenberghe, Weston, MA (US); and Eric Zinn, Lynn, MA (US)
Assigned to Schepens Eye Research Institute, Inc., Boston, MA (US); and Massachusetts Eye and Ear Infirmary, Boston, MA (US)
Filed by Massachusetts Eye and Ear Infirmary, Boston, MA (US); and The Schepens Eye Research Institute, Inc., Boston, MA (US)
Filed on Apr. 27, 2023, as Appl. No. 18/308,590.
Application 18/308,590 is a division of application No. 17/408,104, filed on Aug. 20, 2021.
Application 17/408,104 is a division of application No. 16/906,849, filed on Jun. 19, 2020, granted, now 11,466,258, issued on Oct. 11, 2022.
Application 16/717,942 is a division of application No. 16/179,524, filed on Nov. 2, 2018, granted, now 10,526,584, issued on Jan. 7, 2020.
Application 16/179,524 is a division of application No. 15/633,292, filed on Jun. 26, 2017, granted, now 10,119,125, issued on Nov. 6, 2018.
Application 15/633,292 is a division of application No. 15/291,470, filed on Oct. 12, 2016, granted, now 9,719,070, issued on Aug. 1, 2017.
Application 15/291,470 is a division of application No. 15/095,856, filed on Apr. 11, 2016, granted, now 9,695,220, issued on Jul. 4, 2017.
Application 16/906,849 is a continuation of application No. 16/717,942, filed on Dec. 17, 2019, granted, now 11,104,885, issued on Aug. 31, 2021.
Application 15/095,856 is a continuation in part of application No. PCT/US2014/060163, filed on Oct. 10, 2014.
Claims priority of provisional application 61/889,827, filed on Oct. 11, 2013.
Prior Publication US 2023/0287359 A1, Sep. 14, 2023
Int. Cl. A61K 39/23 (2006.01); A61K 39/00 (2006.01); C07K 14/00 (2006.01); C07K 14/005 (2006.01); C07K 16/22 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01)
CPC C12N 7/00 (2013.01) [A61K 39/00 (2013.01); C07K 14/00 (2013.01); C07K 14/005 (2013.01); C07K 16/22 (2013.01); C12N 15/86 (2013.01); A61K 2039/525 (2013.01); A61K 2039/6075 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); C12N 2750/14121 (2013.01); C12N 2750/14122 (2013.01); C12N 2750/14123 (2013.01); C12N 2750/14141 (2013.01); C12N 2750/14142 (2013.01); C12N 2750/14143 (2013.01); C12N 2750/14171 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A method comprising:
administering a plurality of recombinant adeno-associated virus (rAAV) particles to a subject in need thereof,
wherein each rAAV particle comprises (i) a transgene and (ii) one or more AAV capsid polypeptides that comprise an amino acid sequence according to SEQ ID NOs: 19, 20, 21, 22, 23, 24, 25, or 26, and
wherein the transgene is within the rAAV particle.